BTG....a blockbuster in the making

2007 is going to be a very exciting year for BTG.we start the year with £43m. in the bank. a recurring revenue of some £27m net growing at over 10% pa with interest income of £2m pa.costs are well under conrol.expect progress on alzheimers,sleep apnoea,diabetes,varisolve etc.17th jan is ASCO with Plevitextred trial results for p1/2 gastric cancer due.this product is currently unlicensed.i expect a licencing deal 2007.varisolve should have a marketing/development partner by end 2007.the new focussed BTG will be looking to extract maximum value for shareholders.expect significant income from noncore disposals.new projects..campath to move into p3 for ms..i expect 500p to 600p by this time next year.